One size fits all in prostate cancer: A story tale whose time has come and gone

International Journal of Biological Markers

Volumn 26, Issue 2, 2011, Pages 75-81

  Farooqi, Ammad Ahmad ^a   Bhatti, Shahzad ^a   Nawaz, Ali ^a   Khalid, Ahmad Mukhtar ^a  

^a UNIVERSITY OF LAHORE   (Pakistan)

Author keywords

Androgen receptor (AR); MiRNA; Prostete cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTHRANILIC ACID; ESTROGEN RECEPTOR BETA; KRUPPEL LIKE FACTOR 5; MICRORNA; PROTEOME; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR SOX4; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; CANCER STEM CELL; GENE EXPRESSION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; MALE; MICRORNAS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; PROTEOME; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 79959324895     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8368     Document Type: Article

References (46)

1. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011 Mar 28, doi: 10.1002/pros.21382 [Epub ahead of print].
2. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-30.
3. Jagla M, Feve M, Kessler P, et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007; 148: 4334-43.
4. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011; 71: 2108-17.
5. Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castrationresistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010; 107: 16759-65.
6. Kobayashi M, Huang Y, Jin C, et al. FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells. Prostate 2011 Mar 28, doi: 10.1002/pros.21386 [Epub ahead of print].
7. Reeb CA, Gerlach C, Heinssmann M, et al. A designed cellpermeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode. Endocrinology 2011 April 12 [Epub ahead of print].
8. Kawabata R, Oie S, Oka T, Takahashi M, Kanayama H, Itoh K. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells. Int J Oncol 2011; 38: 665-76.
9. Kawabata R, Oie S, Takahashi M, Kanayama H, Oka T, Itoh K. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines. Int J Oncol 2011; 38: 1489-500.
10. Nakajima Y, Akaogi K, Suzuki T, et al. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ER{beta} and KLF5. Sci Signal 2011; 4: ra22.
11. Leung YK, Ho SM. Estrogen receptor {beta}: switching to a new partner and escaping from estrogen. Sci Signal 2011; 4: pe19.
12. Hu WY, Shi GB, Lam HM, et al. Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells. Endocrinology 2011 Mar 22 [Epub ahead of print].
13. Hirvonen J, Rajalin AM, Wohlfahrt G, Adlercreutz H, Wahala K, Aarnisalo P. Transcriptional activity of estrogenrelated receptor γ (ERRγ) is stimulated by the phytoestrogen equol. J Steroid Biochem Mol Biol 2011; 123: 46-57.
14. Dwyer MA, Joseph JD, Wade HE, et al. WNT11 expression is induced by estrogen-related receptor alpha and betacatenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res 2010; 70: 9298-308.
15. Johnson JJ, Syed DN, Suh Y, et al. Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. Cancer Prev Res (Phila) 2010; 3: 1112-23.
16. Qiao Y, Wang L, Cai LQ, Tan C, Imperato-McGinley J, Zhu YS. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer. J Urol. 2011; 185: 305-14.
17. Taylor SE, Patel II, Singh PB, et al. Elevated oestrogen receptor splice variant ERαΔ5 expression in tumour-adjacent hormone-responsive tissue. Int J Environ Res Public Health 2010; 7: 3871-89.
18. Lavery DN, Villaronga MA, Walker MM, Patel A, Belandia B, Bevan CL. Repression of androgen receptor activity by HEYL, a third member of the hairy/enhancer-of-split-related family of notch effectors. J Biol Chem 2011 March 17 [Epub ahead of print].
19. Uzoh CC, Holly JM, Biernacka KM, et al. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 2011; 104: 1587-93.
20. Roell D, Rosler TW, Degen S, Matusch R, Baniahmad A. Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation. Chem Biol Drug Des 2011 [Epub ahead of print].
21. Pitchakarn P, Suzuki S, Ogawa K, et al. Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. Cancer Lett 2011; 306: 142-50.
22. Wang XL, Kong F, Shen T, Young CY, Lou HX, Yuan HQ. Sesquiterpenoids from myrrh inhibit androgen receptor expression and function in human prostate cancer cells. Acta Pharmacol Sin 2011; 32: 338-44.
23. Hildenbrand ZL, Molugu SK, Herrera N, Ramirez C, Xiao C, Bernal RA. Hsp90 can accommodate the simultaneous binding of the FKBP52 and HOP proteins. Oncotarget 2011; 2: 43-58.
24. Lamoureux F, Thomas C, Yin MJ, et al. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011; 17: 2301-13.
25. Liu R, Zhou Z, Huang J, Chen C. PMEPA1 promotes androgen receptor-negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21 Cip1 signaling pathway. J Pathol 2011; 223: 683-94.
26. Barboro P, Repaci E, Ferrari N, Rubagotti A, Boccardo F, Balbi C. Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. Prostate 2011 Feb 14, doi: 10.1002/pros.21366 [Epub ahead of print].
27. Kawabata R, Oie S, Oka T, Takahashi M, Kanayama H, Itoh K. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells. Int J Oncol 2011; 38: 665-76.
28. Kampa M, Theodoropoulou K, Mavromati F, et al. Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer. J Pharmacol Exp Ther 2011; 337: 24-32.
29. Thomas C, Zoubeidi A, Kuruma H, et al. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 2011; 10: 347-59.
30. Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 2009; 69: 709-17.
31. Bonci D, Coppola V, Musumeci M, et al. The miR-15amiR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-7.
32. Porkka KP, Ogg EL, Saramaki OR, et al. The miR-15amiR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer 2011; 50: 499-509.
33. Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol 2011 Apr 13 [Epub ahead of print].
34. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn 2011; 11: 259-75.
35. Tang X, Tang X, Gal J, Kyprianou N, Zhu H, Tang G. Detection of microRNAs in prostate cancer cells by microRNA array. Methods Mol Biol 2011; 732: 69-88.
36. Wach S, Nolte E, Szczyrba J, et al. MiRNA profiles of prostate carcinoma detected by multi-platform miRNA screening. Int J Cancer 2011 Mar 11 [Epub ahead of print].
37. Hao Y, Zhao Y, Zhao X, et al. Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest 2011; 29: 318-24.
38. Chiyomaru T, Tatarano S, Kawakami K, et al. SWAP70, actinbinding protein, function as an oncogene targeting tumorsuppressive miR-145 in prostate cancer. Prostate 2011 Feb 25 [Epub ahead of print].
39. Hagman Z, Larne O, Edsjo A, et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 2010; 127: 2768-76.
40. Gordanpour A, Stanimirovic A, Nam RK, et al. miR-221 is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer. Anticancer Res 2011; 31: 403-10.
41. Ostling P, Leivonen SK, Aakula A, et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011; 71: 1956-67.
42. Kowarsch A, Preusse M, Marr C, Theis FJ. miTALOS: Analyzing the tissue-specific regulation of signaling pathways by human and mouse microRNAs. RNA 2011; 17: 809-19.
43. Albertini MC, Olivieri F, Lazzarini R, et al. Predicting microRNA modulation in human prostate cancer using a simple String IDentifier (SID1.0). J Biomed Inform 2011 Feb 18 [Epub ahead of print].
44. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
45. Farooqi AA, Mansoor Q, Ismail M, Bhatti S. Therapeutic effect of epigallocatechin-3-gallate (EGCG) and silibinin on ATM dynamics in prostate cancer cell line LNCaP. World Journal of Oncology 2010; 1: 242-6.
46. Farooqi AA, Bhatti S, Rana A, et al. Shattering the underpinnings of neoplastic architecture in LNCaP: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation. J Exp Ther Oncol 2011 (in press).